Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1

Bioconjugate Chemistry

Volumn 15, Issue 5, 2004, Pages 1110-1117

  Cruz, Luis J ^a   Iglesias, Enrique ^b   Aguilar, Julio C ^b   Cabrales, Ania ^b   Reyes, Osvaldo ^b   Andreu, David ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; DISEASES; EPITOPES; IMMUNIZATION; MAMMALS; MIXTURES; RECOMBINANT PROTEINS; VACCINES; VIRUSES;

ANTIBODIES RESPONSE; BINDING PEPTIDE; CROSS-REACTIVITY; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOGENS; MULTIPLE ANTIGEN PEPTIDES; NEUTRALISATION; SURFACE ANTIGEN;

PEPTIDES;

ANTIGEN; CD4 ANTIGEN; CELLULOSE; HEPATITIS B SURFACE ANTIGEN; PEPTIDE; VASOPRESSIN V3 RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CONJUGATE; CROSS REACTION; EPITOPE MAPPING; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; SEROCONVERSION; TECHNIQUE; VIRUS NEUTRALIZATION;

ANIMALIA; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 4644279789     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc049944u     Document Type: Article

References (34)

1. Poignard, P., Saphire, E. O., Parren, P. W., and Burton, D. R. (2001) gp120: Biologic aspects of structural features. Annu. Rev. Immunol. 19, 253-274.
2. Birx, D. L., Loomis-Price, L. D., Aronson, N., Brundage, J., Davis, C., Deyton, L., Garner, R., Gordin, F., Henry, D., Holloway, W., Kerkering, T., Luskin-Hawk, R., McNeil, J., Michael, N., Foster, P. P., Poretz, D., Ratto-Kim, S., Renzullo, P., Ruiz, N., Sitz, K, Smith, G., Tacket, C., Thompson, M., Tramont, E., Yangco, B., Yarrish, R., and Redfield, R. R. (2000) Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J. Infect. Dis. 181, 881-889.
3. Girard, M., Yue, L., Barre-Sinoussi, F., van der Ryst, E., Meignier, B., Muchmore, E., and Fultz, P. N. (1996) Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J. Virol. 70, 8229-8233.
4. Vazquez-Blomquist, D., Gonzalez, S., and Duarte, C. A. (2002) Effect of promoters on cellular immune response induced by recombinant fowlpox virus expressing multi-epitope polypeptides from HIV-1. Biotechnol. Appl. Biochem. 36, 171-179.
5. Kim, J. J., Yang, J. S., Manson, K. H., and Weiner, D. B. (2001) Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 19, 2496-2505.
6. Lambert, J. S., Keefer, M., Mulligan, M. J., Schwartz, D., Mestecky, J., Weinhold, K., Smith, C., Hsieh, R., Moldoveanu, Z., Fast, P., Forrest, B., and Koff, W. (2001) A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 19, 3033-3042.
7. Aguilar, A., Carrazana, Y., and Duarte, C. A. (2001) Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1. Biomol. Eng. 18, 117-124.
8. Toledo, H., Baly, A., Castro, O., Resik, S., Lamerte, J., Rolo, F., Navea, L., Lovaina, L., Cruz, O., Miguez, J., Serrano, T., Sierra, B., Perez, L., Ricardo, M. E., Debed, M., Lubian, A. L., Blanco, M., Millan, J. C., Ortega, A., Iglesias, E., Penton, E., Martin, Z., Ferez, J., Diaz, M., and Duarte, C. A. (2001) A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19, 4328-4336.
9. Cruz, L. J., Quintana, D., Iglesias, E., García, Y., Huerta, V., Garay, H. E., Duarte, C., and Reyes, O. (2000) Immunogenicity Comparison of a Multi-antigenic Peptide Bearing V3 Sequences of the Human Immunodeficiency Virus Type 1 with TAB9 Protein in Mice. J. Peptide Sci. 6, 217-224.
10. Nardelli, B., Lu, Y. A., Shiu, D. R., Delpierre-Defoort, C., Profy, A. T., and Tam, J. P. (1992) A chemically defined synthetic vaccine model for HIV-1. J. Immunol. 148, 914-920.
11. Barouch, D. H., and Letvin, N. L. (2000) Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys. Dev. Biol. 104, 85-92.
12. Lifson, J. D., and Martin, M. A. (2002) One step forwards, one step back. Nature 415, 272-273.
13. Moore, J. P., and Nara, P. L. (1991) The role of the V3 loop in HIV infection. AIDS 5, 521-533.
14. Lenz, J., Su, M., Mizrachi, Y., Burke, M., and Rubinstein, A. (2001) V3 variation in HIV-seropositive patients receiving a V3-targeted vaccine. AIDS 15, 577-581.
15. Cardonnier, A., Montagnier, L., and Emerman, M. (1989) Single amino acid changes in HIV envelope affect viral tropism and receptor binding. Nature 340, 571-574.
16. Tian, H., Lan, C., and Chen, Y. H. (2002) Sequence variation and consensus sequence of V3 loop on HIV-1 gp120. Immunol. Lett. 83, 231-233.
17. Masse, H. G., Ameisen, J. C., Boutillon, C., Rouaix, F., Bossus, M., Deprez, B., Neyrinck, J. L., Capron, A., and Tartar, A. (1992) Synthetic Vaccines and HIV-1 hypervariability: a "mixotope" approach. Pept. Res. 5, 211-215.
18. Estaquier, J., Gras-Masse, H., Boutillon, C., Ameisen, J. C., Capron, A., Tartar, A., and Auriault, C. (1994) The mixotope: a combinatorial peptide library as a T cell and B cell immunogen. Eur. J. Immunol. 24, 2789-2795.
19. Gras-Masse, H., Boutillon, C., Dieses, E., Deprez, B., and Tartar, A. (1997) Confronting the degeneracy of convergent combinatorial immunogens, or "mixotopes", with the specificity of recognition of the target sequences. Vaccine 15, 1568-1578.
20. Neurath, A. R., and Strick, N. (1990) Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) Mol. Immunol. 27, 539-549.
21. Smith, A. D., Geisler, S. C., Chen, A. A., Resnick, D. A., Roy, B. M., Lewi, P. J., Arnold, E., and Arnold, G. F. (1998) Human rhinovirus type 14: human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J. Virol. 72, 651-659.
22. Houghten, R. A., Graw, S. T., and Bray, M. K. (1986) Simultaneous multiple peptide synthesis: The rapid preparation of large numbers of discrete peptides for biological, immunological and methodological studies. BioTechniques 4, 522-526.
23. Kaiser, E., Colescott, R. L., Bossinger, C. D., and Cook, P. I. (1970) Color test for detection of free terminal amino groups in solid-phase synthesis of peptides. Anal. Biochem. 34, 595-598.
24. Ellman, G. L. (1959) Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82, 70-77.
25. Mo, W., Sakamoto, H., Nishikawa, A., Kagi, N., Langridge, J. I., Shimonishi, Y., and Takao, T. (1999) Structural characterization of chemically derivatized oligosaccharides by nanoflow electrospray ionization mass spectrometry. Anal. Chem. 71, 4100-4106.
26. Deen, C., Claassen, E., Gerritse, K, Zegers, N. D., and Boersma, W. J. A. (1990) A novel carbodiimide coupling method for synthetic peptides: Enhanced antipeptide antibody responses. J. Immunol. Methods 129, 119-125.
27. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
28. Gomez, C. E., Lopez-Campistrous, A. E., and Duarte, C. A. (1998) An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 + Human sera. J. Virol. Methods 71, 7-16.
29. Frank, R. (1992) Spot-Synthesis: An easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 48, 9217-9232.
30. Tarn, J. P. (1988) Synthetic peptide vaccine design: synthetic and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U.S.A. 86, 5409-5413.
31. Cruz, L. J., Iglesias, E., Aguilar, J. C., Quintana, D., Garay, H. E., Duarte, C., and Reyes, O. (2001) Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J. Pept. Sci. 7, 511-518.
32. Cruz, L. J., Iglesias, E., Aguilar, J. C., Gonzalez, L. J., Reyes, O., Albericio, F., and Andreu, A. (2004) A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjugate Chem. 15, 112-120.
33. Hewer, R., and Meyer, D. (2003) Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/ AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol. Immunol. 40, 327-335.
34. Resnick, D. A., Smith, A. D., Gesiler, S. C., Zhang, A., Arnold, E., and Arnold, G. F. (1995) Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1. J. Virol. 4, 2406-2411.